Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity.
Purple Biotech Ltd.’s Board of Directors sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.
| Audit Committee | Compensation Committee | |
| Independent Directors | ||
| Dr. Eric Rowinsky | ||
| Ido Agmon | ![]() |
|
| Robert Gagnon | ![]() |
|
| Suzana Nahum-Zilberberg | ![]() |
![]() |
| Yael Margolin | ![]() |
|
| Non-independent Directors | ||
| Isaac Israel | ![]() |
|
| Gil Efron | ||
Member
Chair